In the context of pulmonary hypertension, for example, erythropoietin and sildenafil may be promising drugs for protecting endothelial cells, decreasing the dysfunction of these cells after hypoxia, which is an event that can occur in AKI after Bothrops snakebite in ischemia/reperfusion (I/R) injury (Albuquerque et al., 2020; Gammella et al., 2013). Here, EPO is linked to pulmonary hypertension.